Indaptus Therapeutics Files Routine 8-K; No Major Changes Reported
Ticker: INDP · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, regulatory-filing
TL;DR
**Indaptus Therapeutics filed a standard 8-K, nothing major to see here.**
AI Summary
Indaptus Therapeutics, Inc. filed an 8-K on January 23, 2024, reporting an event on January 22, 2024. This filing is a routine current report, indicating no major changes to the company's structure or operations, such as amendments to articles of incorporation or bylaws, or changes in fiscal year, despite those being listed as potential item information. For investors, this means there's no immediate news of significant corporate actions that would drastically alter the stock's value or the company's strategic direction, suggesting a period of operational stability.
Why It Matters
This filing indicates business as usual for Indaptus Therapeutics, Inc., with no immediate red flags or catalysts for significant stock movement based on corporate structural changes.
Risk Assessment
Risk Level: low — The filing is a routine current report with no disclosed events that would introduce new risks or significant changes to the company's operations or financial standing.
Analyst Insight
A smart investor would note this as a non-event filing, indicating no immediate corporate actions that would impact the stock. Further research into the company's operational performance and pipeline would be more relevant than this particular 8-K.
Key Numbers
- 001-40652 — Commission File Number (Identifies the company's registration with the SEC.)
- 86-3158720 — IRS Employer Identification No. (Standard identification for tax purposes.)
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — the registrant filing the 8-K
- Nasdaq Capital Market (company) — the exchange where Indaptus Therapeutics' common stock is registered
- 001-40652 (dollar_amount) — Commission File Number
- 86-3158720 (dollar_amount) — IRS Employer Identification No.
- January 22, 2024 (date) — Date of earliest event reported
FAQ
What is the purpose of this 8-K filing by Indaptus Therapeutics, Inc.?
This 8-K filing is a 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' and was filed on January 23, 2024, for an event that occurred on January 22, 2024. It appears to be a routine filing, as no specific material events like amendments to articles or bylaws, or changes in fiscal year, were detailed despite being listed as potential item information.
What is the trading symbol and exchange for Indaptus Therapeutics, Inc. common stock?
The common stock of Indaptus Therapeutics, Inc. has a trading symbol of 'INDP' and is registered on the Nasdaq Capital Market.
What is the state of incorporation for Indaptus Therapeutics, Inc.?
Indaptus Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Indaptus Therapeutics, Inc.?
The business address of Indaptus Therapeutics, Inc. is 3 Columbus Circle, 15th Floor, New York, New York, 10019.
Does this 8-K filing indicate any changes to the company's articles of incorporation or bylaws?
While 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' is listed under 'ITEM INFORMATION', the body of this specific 8-K filing does not provide any details or confirm that such changes have actually occurred. It appears to be a standard cover sheet for a current report without specific event disclosures in the provided text.
Filing Stats: 734 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2024-01-23 16:05:34
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INDP Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex3-1.htm (EX-3.1) — 199KB
- 0001493152-24-003441.txt ( ) — 452KB
- indp-20240122.xsd (EX-101.SCH) — 3KB
- indp-20240122_lab.xml (EX-101.LAB) — 33KB
- indp-20240122_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 23, 2024 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer